Buyback and new drugs offset a first-half loss
Buyback loan backs share cancellation plan ICBC committed up to 180 million yuan for a buyback loan, matching the company's plan to spend 100-200 million yuan repurchasing and cancelling shares. Cancelling shares shrinks the share count, which can lift the value of each remaining share and signals management thinks the stock is cheap.
The loan plus the repurchase-and-cancel plan is the clearest force supporting the share price this period.
Subsidiary adds two products to its pipeline Lummy Pharmaceutical bought global rights to a vitamin D soft capsule for 28 million yuan and won approval to make and sell an inhaled acetylcysteine solution in China. More products broaden future sales sources, though profits from them will take time to show.
These are the only new operating developments that could add future revenue, balancing the weak earnings news.
First-half swing to a 48.8 million yuan loss Revenue fell 29.69% to 725 million yuan and the company swung from a 25.91 million yuan profit to a 48.8 million yuan loss. Industry policy hurt core products, finance costs rose and fund investment income fell. This weak result is the main drag on the stock.
The interim loss is the biggest fundamental negative and directly explains why the stock faces pressure.
Some underlying signs hold up despite the loss Operating cash inflow rose by 110 million yuan to 40.91 million yuan, the debt ratio is a moderate 34.09%, and gross margin improved to 50.90% for a second year. These show the core business still generates cash, softening the loss's impact.
It gives the fair counterweight: not everything in the weak report was bad, which matters for judging the stock.